Imagine if doctors could take a biopsy of a tumor without using a needle or cutting the skin. This technology adds a special plug-and-play coil to existing MRI machines to 'see' the chemistry of a tumor. It helps doctors figure out if a specific chemotherapy is working without needing to draw blood or perform surgery.
Traditional cancer biopsies are invasive, require blood or tissue sampling, and can be slow. This creates a gap in rapidly adjusting chemotherapy plans based on real-time tumor metabolic response.
A plug-and-play RF breast coil add-on for MRI scanners and associated scan protocols for metabolic biomarker detection.
If you are a hardware manufacturer dealing with the need for specialized diagnostic add-ons — this project developed a plug-and-play RF breast coil that provides metabolic data. This allows existing MRI machines to perform virtual biopsies without replacing the entire system.
If you are a clinic dealing with the slow process of verifying chemotherapy efficacy via invasive biopsies — this project developed a Metabolic MRI-as-a-Service solution. It provides rapid, non-invasive predictive data to guide treatment plans.
If you are a reimbursement provider dealing with high costs of ineffective cancer treatments — this project developed a tool to identify tumor activity and biomarkers. This ensures patients receive the best-fitting treatment plan based on their specific tumor characteristics.
The project is introducing a 'Metabolic MRI-as-a-Service' business model to make the tool accessible and affordable, though specific pricing figures are not provided in the data.
The project is currently in the prototype phase, having developed a pre-production model and performed initial tests on RF breast coils.
Based on available project data, the technology is being developed by a consortium led by WaveTronica BV, but specific licensing terms are not listed.
The device is designed as a plug-and-play add-on for existing MRI scanners, requiring no major infrastructure changes.
The project period runs from 2022-05-01 to 2025-07-31, suggesting a transition toward market readiness by mid-2025.
The consortium is lean and highly specialized, consisting of 4 partners across 3 countries (NL, DE, PL). It features a strong balance between commercial drive and academic validation, with 1 SME (WaveTronica), 2 universities, and 1 research center. The 25% industry ratio is bolstered by external support from a reimbursement company (VGZ) and Tesla DC, indicating a strong bridge between lab research and market demand.
Contact WaveTronica BV in the Netherlands
Contact us to explore licensing opportunities for Metabolic MRI-as-a-Service.
